{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:09:57Z","timestamp":1790885397660,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg\/m2 and PegLD on day 4 at 30 mg\/m2 to 42 patients with advanced hematologic malignancies. Grade 3 or 4 toxicities in at least 10% of patients included thrombocytopenia, lymphopenia, neutropenia, fatigue, pneumonia, peripheral neuropathy, febrile neutropenia, and diarrhea. The MTD based on cycle 1 was 1.50 and 30 mg\/m2 of bortezomib and PegLD, respectively. However, due to frequent dose reductions and delays at this level, 1.30 and 30 mg\/m2 are recommended for further study. Pharmacokinetic and pharmacodynamic studies did not find significant drug interactions between these agents. Antitumor activity was seen against multiple myeloma, with 8 of 22 evaluable patients having a complete response (CR) or near-CR, including several with anthracycline-refractory disease, and another 8 having partial responses (PRs). One patient with relapsed\/refractory T-cell non-Hodgkin lymphoma (NHL) achieved a CR, whereas 2 patients each with acute myeloid leukemia and B-cell NHL had PRs. Bortezomib\/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen.<\/jats:p>","DOI":"10.1182\/blood-2004-07-2911","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T01:13:08Z","timestamp":1104455588000},"page":"3058-3065","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":239,"title":["Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies"],"prefix":"10.1182","volume":"105","author":[{"given":"Robert Z.","family":"Orlowski","sequence":"first","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynaldo A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa D.","family":"Hall","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred J.","family":"Kudrik","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Allred","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandhi R.","family":"Johri","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Jones","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik W.","family":"Van Deventer","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don A.","family":"Gabriel","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly S.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Adams","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie-Lee","family":"Esseltine","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Trehu","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Green","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Lehman","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Natoli","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Collins","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Lindley","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Claire","family":"Dees","sequence":"additional","affiliation":[{"name":"From The Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology\/Oncology, Department of Biostatistics, and School of Pharmacy, all of University of North Carolina at Chapel Hill, Chapel Hill, NC; and Millennium Pharmaceuticals, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021220182026900_REF1","doi-asserted-by":"crossref","unstructured":"Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays. 2000;22:442-451.","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q"},{"key":"2020021220182026900_REF2","unstructured":"Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9:6316-6325."},{"key":"2020021220182026900_REF3","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622."},{"key":"2020021220182026900_REF4","unstructured":"Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076."},{"key":"2020021220182026900_REF5","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.","DOI":"10.1182\/blood.V99.11.4079"},{"key":"2020021220182026900_REF6","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.","DOI":"10.1074\/jbc.M200360200"},{"key":"2020021220182026900_REF7","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379.","DOI":"10.1073\/pnas.202445099"},{"key":"2020021220182026900_REF8","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.","DOI":"10.1182\/blood-2002-08-2543"},{"key":"2020021220182026900_REF9","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.","DOI":"10.1200\/JCO.2002.01.133"},{"key":"2020021220182026900_REF10","doi-asserted-by":"crossref","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.","DOI":"10.1056\/NEJMoa030288"},{"key":"2020021220182026900_REF11","doi-asserted-by":"crossref","unstructured":"Blade\u0301 J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"2020021220182026900_REF12","doi-asserted-by":"crossref","unstructured":"Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: a phase 3 randomized study [abstract]. Proc Amer Soc Clin Oncol. 2004;23:558. Abstract 6511.","DOI":"10.1200\/jco.2004.22.14_suppl.6511"},{"key":"2020021220182026900_REF13","doi-asserted-by":"crossref","unstructured":"Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21:4239-4247.","DOI":"10.1200\/JCO.2003.06.001"},{"key":"2020021220182026900_REF14","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002;8:385-389.","DOI":"10.1016\/S1471-4914(02)02375-4"},{"key":"2020021220182026900_REF15","doi-asserted-by":"crossref","unstructured":"Loo TW, Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J. 1999;13:1724-1732.","DOI":"10.1096\/fasebj.13.13.1724"},{"key":"2020021220182026900_REF16","unstructured":"Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1:841-849."},{"key":"2020021220182026900_REF17","doi-asserted-by":"crossref","unstructured":"Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44\/42-MAPK. J Pharmacol Exp Ther. 2003;307:861-869.","DOI":"10.1124\/jpet.103.055806"},{"key":"2020021220182026900_REF18","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101:2377-2380.","DOI":"10.1182\/blood-2002-06-1768"},{"key":"2020021220182026900_REF19","unstructured":"Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136-1144."},{"key":"2020021220182026900_REF20","doi-asserted-by":"crossref","unstructured":"Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol. 2000;11:1029-1033.","DOI":"10.1023\/A:1008365716693"},{"key":"2020021220182026900_REF21","doi-asserted-by":"crossref","unstructured":"Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an anti-apoptotic role. Mol Pharmacol. 2004;66:1478-1490.","DOI":"10.1124\/mol.104.003400"},{"key":"2020021220182026900_REF22","doi-asserted-by":"crossref","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.","DOI":"10.1159\/000180580"},{"key":"2020021220182026900_REF23","doi-asserted-by":"crossref","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000; 46:673-683.","DOI":"10.1093\/clinchem\/46.5.673"},{"key":"2020021220182026900_REF24","doi-asserted-by":"crossref","unstructured":"Gabizon A, Chisin R, Amselem S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer. 1991;64:1125-1132.","DOI":"10.1038\/bjc.1991.476"},{"key":"2020021220182026900_REF25","unstructured":"Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987-992."},{"key":"2020021220182026900_REF26","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511."},{"key":"2020021220182026900_REF27","doi-asserted-by":"crossref","unstructured":"Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160-2168.","DOI":"10.1002\/cncr.10946"},{"key":"2020021220182026900_REF28","doi-asserted-by":"crossref","unstructured":"Kiyomiya K, Matsuo S, Kurebe M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci. 1998;62:1853-1860.","DOI":"10.1016\/S0024-3205(98)00151-9"},{"key":"2020021220182026900_REF29","doi-asserted-by":"crossref","unstructured":"Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z"},{"key":"2020021220182026900_REF30","doi-asserted-by":"crossref","unstructured":"Goy A, Younes A, McLaughlin P, et al. Update on a phase 2 study of bortezomib in patients with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas [abstract]. Proc Amer Soc Clin Oncol. 2004;23:575. Abstract 6581.","DOI":"10.1200\/jco.2004.22.14_suppl.6581"},{"key":"2020021220182026900_REF31","doi-asserted-by":"crossref","unstructured":"O'Connor OA. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular and mantle cell lymphoma [abstract]. Proc Amer Soc Clin Oncol. 2004;23:576. Abstract 6582.","DOI":"10.1200\/jco.2004.22.90140.6582"},{"key":"2020021220182026900_REF32","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62:1083-1086."},{"key":"2020021220182026900_REF33","unstructured":"Yang HH, Swift R, Sadler K, et al. A phase I\/II trial of VELCADE and melphalan combination therapy for patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2003;102:235a. Abstract 826"},{"key":"2020021220182026900_REF34","doi-asserted-by":"crossref","unstructured":"Barlogie B, Shaughnessy JD, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.","DOI":"10.1182\/blood-2003-04-1045"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3058\/1709967\/zh800805003058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3058\/1709967\/zh800805003058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:38:20Z","timestamp":1581557900000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/8\/3058\/20613\/Phase-1-trial-of-the-proteasome-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-07-2911","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,15]]}}}